Debate Over Addyi Flares Anew
Posted on March 01, 2016
Source:
Medpage Today
A review of eight clinical trials testing flibanserin (Addyi), the first and only drug on the market to treat hypoactive sexual desire disorder (HSDD) in women, concluded the drug performed on the low end of the clinical efficacy range used to gain FDA approval. However, women's health experts argue that the drug earned its approval and should remain in the treatment arsenal.